Get started
Author

Maximilian T. Lobmeyer

Observed names: Lobmeyer, Maximilian, Lobmeyer, Maximilian T., M LOBMEYER, M Lobmeyer, Maximilian Lobmeyer, Maximilian T Lobmeyer, Maximilian T. Lobmeyer
Observed institutions: University of Maryland, Baltimore, Mayo Clinic, Boehringer Ingelheim (Germany), Emory University, Washington University in St. Louis, University of South Florida, University of Florida Health, University of Florida, Bayer (Germany), University of Missouri–Kansas City, The University of Texas Health Science Center at Houston
ORCID: 0009-0004-7307-0103
Observed ORCID: 0009-0004-7307-0103
OpenAlex ID: A5012714760
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
2013 · John W. Eikelboom, Stuart J. Connolly, et al. · New England Journal of Medicine · 1,509
Large-Scale Gene-Centric Meta-Analysis across 39 Studies Identifies Type 2 Diabetes Loci
2012 · Richa Saxena, Clara C. Elbers, et al. · The American Journal of Human Genetics · 270
PDF
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height
2010 · Matthew B. Lanktree, Yiran Guo, et al. · The American Journal of Human Genetics · 133
PDF
Effect of Protein Binding on the Pharmacological Activity of Highly Bound Antibiotics
2008 · Stephan Schmidt, Katharina Röck, et al. · Antimicrobial Agents and Chemotherapy · 113
Synergistic polymorphisms of β1 and α2C-adrenergic receptors and the influence on left ventricular ejection fraction response to β-blocker therapy in heart failure
2007 · Maximilian T. Lobmeyer, Yan Gong, et al. · Pharmacogenetics and Genomics · 83
Relation of β2-Adrenoceptor Haplotype to Risk of Death and Heart Transplantation in Patients With Heart Failure
2006 · Jaekyu Shin, Maximilian T. Lobmeyer, et al. · The American Journal of Cardiology · 83
G protein receptor kinase 4 polymorphisms
2012 · Alexander G. Vandell, Maximilian T. Lobmeyer, et al. · Hypertension · 70
PDF
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients
2010 · Maximilian T. Lobmeyer, Liewei Wang, et al. · Pharmacogenetics and Genomics · 59
Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies
2020 · Michael Boettcher, Michael Gerisch, et al. · Clinical Pharmacokinetics · 58
PDF
α-Adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: Results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES)
2008 · Tobias Gerhard, Yan Gong, et al. · American Heart Journal · 50
Comparison of Cytochrome P450 2C9 Genotyping Methods and Implications for the Clinical Laboratory
2004 · Christina L. Aquilante, Maximilian T. Lobmeyer, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 43
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients
2021 · Stefan Willmann, Eleonora Marostica, et al. · CPT Pharmacometrics & Systems Pharmacology · 38
PDF
Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents
2016 · Thorsten Lehr, Lisa Cronin, et al. · Thrombosis and Haemostasis · 35
Chromosome 9p21 Haplotypes and Prognosis in White and Black Patients With Coronary Artery Disease
2011 · Yan Gong, Amber L. Beitelshees, et al. · Circulation Cardiovascular Genetics · 34
PDF
Genome‐Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β‐Blockers
2018 · Mohamed H. Shahin, Daniela J. Conrado, et al. · Journal of the American Heart Association · 24
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation
2013 · Eunice L. Kwak, Geoffrey I. Shapiro, et al. · Cancer · 24
Impact of Genetic Polymorphisms of SLC2A2, SLC2A5, and KHK on Metabolic Phenotypes in Hypertensive Individuals
2013 · MyPhuong T. Le, Maximilian T. Lobmeyer, et al. · PLoS ONE · 19
PDF
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
2026 · Howard Trachtman, Matthias Kretzler, et al. · The Lancet · 15
Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide
2010 · Julio D. Duarte, Maximilian T. Lobmeyer, et al. · Pharmacogenetics and Genomics · 13
Large-Scale Gene-Centric Meta-Analysis across 39 Studies Identifies Type 2 Diabetes Loci
2012 · Richa Saxena, Clara C. Elbers, et al. · The American Journal of Human Genetics · 12
PDF
β2‐Adrenergic Receptor Gene Affects the Heart Rate Response of β‐Blockers: Evidence From 3 Clinical Studies
2019 · Mohamed H. Shahin, Nihal El Rouby, et al. · The Journal of Clinical Pharmacology · 11
Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat
2023 · Sebastian Frechen, Ibrahim Ince, et al. · CPT Pharmacometrics & Systems Pharmacology · 8
PDF
Results from in vitro and in vivo studies evaluating the bioavailability, effects of food, and administration as crushed tablet suspension on vericiguat pharmacokinetics
2022 · Corina Becker, Michael Boettcher, et al. · AAPS Open · 7
PDF
Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment
2025 · Armin Schultz, Atef Halabi, et al. · Expert Opinion on Investigational Drugs · 6
PDF
New Insights Into Hepatic Impairment ( HI ) Trials
2025 · Sebastian Haertter, Maximilian Lobmeyer, et al. · Clinical and Translational Science · 6
PDF
Works count: 42
Citation count: 2,736
H-index: 17
I10-index: 21
Year
Topic
Type